文献速递浆细胞疾病

TP53双等位基因失活的转录特征识别出一组无此遗传学异常但预后极差的多发性骨髓瘤患者

Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome.
PubMed 文献 · Br J Haematol · 2022-08-18

研究分析MMRF CoMMpass研究中660例新诊断多发性骨髓瘤患者的RNA测序、全基因组和全外显子测序数据,刻画TP53双等位基因失活(DH-TP53)的转录特征。基于78个仅在DH-TP53患者中异常调控的基因构建评分,识别出50例无TP53双等位基因失活但转录谱相似(DH-TP53样)且预后极差的患者,中位总生存<2年。该评分的预后价值在850例经微阵列分析的新诊断患者中获外部验证,并可细化基于细胞遗传学异常和ISS的传统预后分层。

要点

  • 基于78个DH-TP53特异异常调控基因构建的评分识别出50例无TP53双等位基因失活但转录谱相似的患者。
  • DH-TP53样组预后极差,中位总生存<2年。
  • DH-TP53评分在850例新诊断患者中获外部验证,并可细化细胞遗传学和ISS分层。

核心结论

  • 基于78个仅在DH-TP53患者中异常调控基因的评分,可识别出无TP53双等位基因失活但转录谱相似且预后极差(中位OS<2年)的多发性骨髓瘤患者。

研究设计与样本

  • 分析MMRF CoMMpass研究中660例新诊断多发性骨髓瘤患者的RNA测序、全基因组和全外显子测序数据,刻画DH-TP53的转录特征。
  • 使用850例经微阵列分析的新诊断多发性骨髓瘤患者的基因表达数据进行外部验证。

主要发现

  • 发现78个仅在DH-TP53患者中异常调控的基因。
  • 基于这些基因的评分识别出50例共享相同转录谱(DH-TP53样组)的患者,其中位总生存<2年,尽管这些患者不携带TP53双等位基因失活。
  • DH-TP53评分的预后价值在850例新诊断多发性骨髓瘤患者中获外部验证。
  • DH-TP53评分细化了基于细胞遗传学异常和国际分期系统(ISS)的传统预后分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Biallelic inactivation of TP53 has been included in the definition of double-hit (DH) multiple myeloma (MM), which entails an ominous prognosis. However, this condition, or even the presence of high-risk cytogenetic abnormalities, cannot accurately capture the 15%-20% of the MM population with a median overall survival below 24 months. This prompted us to look for other MM patients who might have transcriptional characteristics similar to those with DH-TP53. In the present study, we analysed RNA-seq, whole-genome and whole-exome sequencing data from 660 newly diagnosed MM (NDMM) patients from the MMRF (Multiple Myeloma Research Foundation) CoMMpass study to characterize the transcriptional signature of TP53 double-hit (DH-TP53) MM. We found 78 genes that were exclusively deregulated in DH-TP53 patients. A score based on these genes identified a group of 50 patients who shared the same transcriptional profile (DH-TP53-like group) whose prognosis was particularly unfavourable [median overall survival (OS) < 2 years], despite not harbouring the biallelic inactivation of TP53. The prognostic value of the DH-TP53 score was externally validated using gene expression data from 850 NDMM patients analysed by microarrays. Furthermore, our DH-TP53 score refined the traditional prognostic stratification of MM patients according to the cytogenetic abnormalities and International Staging System (ISS).

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. De Ramón C, Rojas EA, Cardona-Benavides IJ, et al. Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome. Br J Haematol. 2022. PMID: 35983648. doi:10.1111/bjh.18410

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。